Published in Am J Respir Crit Care Med on May 13, 2005
Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med (2012) 1.47
Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med (2007) 1.24
Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med (2013) 0.98
Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med (2012) 0.84
Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant (2015) 0.82
Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis. Thorax (2007) 0.82
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Ann Am Thorac Soc (2016) 0.80
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.77
Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med (2014) 0.76
How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood (2016) 0.75
Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: Daily home spirometry versus standard pulmonary function testing. Can J Respir Ther (2014) 0.75
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant (2002) 5.49
Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med (2002) 2.64
Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant (1998) 1.63
Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol (1996) 1.58
Bronchiolitis obliterans after lung transplantation: a review. Chest (1998) 1.45
The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report--2003. J Heart Lung Transplant (2003) 1.37
Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A (1992) 1.36
The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med (2003) 0.97
Spirometry values in stable lung transplant recipients. Am J Respir Crit Care Med (1997) 0.89
Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med (2000) 0.88
Limitations of spirometry in detecting rejection after single-lung transplantation. Am J Respir Crit Care Med (1994) 0.86
Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. J Heart Lung Transplant (2003) 0.85
Nonparametric rank-based methods for group sequential monitoring of paired censored survival data. Biometrics (2000) 0.84
Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second. J Heart Lung Transplant (1996) 0.82
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci (2009) 2.78
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol (2006) 2.68
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol (2004) 2.51
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Greater neural pattern similarity across repetitions is associated with better memory. Science (2010) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med (2006) 2.28
Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. J Immunol (2002) 2.27
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2007) 2.19
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol (2003) 2.14
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J (2005) 2.09
The solitary pulmonary nodule. Chest (2003) 2.09
A frozen hell. Nature (2011) 2.07
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc (2013) 2.05
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun (2004) 2.04
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol (2005) 2.01
Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol (2008) 2.00
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis (2002) 1.98
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98
Leptin corrects host defense defects after acute starvation in murine pneumococcal pneumonia. Am J Respir Crit Care Med (2005) 1.97
Significance of the microbiome in obstructive lung disease. Thorax (2012) 1.97
Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol (2005) 1.93